/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

SOLID BIOSCIENCES INC Share Price Today: Live Updates & Key Insights

SOLID BIOSCIENCES INC share price today is $7.61, up -0.06%. The stock opened at $7.41 against the previous close of $7.715, with an intraday high of $7.92 and low of $7.26.

SOLID BIOSCIENCES INC Share Price Chart

style
pb-0

SOLID BIOSCIENCES INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

SOLID BIOSCIENCES INC Share Price Performance

$7.61 -0.0006(-0.06%) SLDB at 13 Mar 2026 03:15 PM Biotechnology
Lowest Today 7.26
Highest Today 7.92
Today’s Open 7.41
Prev. Close 7.715
52 Week High 8.72
52 Week Low 2.41
Day’s Range: Low 7.26 High 7.92
52-Week Range: Low 2.41 High 8.72
1 day return -
1 Week return +14.3
1 month return +24.95
3 month return +34.9
6 month return +39.92
1 year return +49.7
3 year return +54.2
5 year return -94.61
10 year return -

SOLID BIOSCIENCES INC Institutional Holdings

Perceptive Advisors LLC 15.19

Bain Capital Life Sciences Investors, LLC 10.15

Siren, L.L.C. 9.87

Vestal Point Capital LP 7.46

RA Capital Management, LLC 7.46

BlackRock Inc 6.06

Vanguard Group Inc 4.43

Armistice Capital, LLC 3.35

Citadel Advisors Llc 3.33

Vanguard Total Stock Mkt Idx Inv 2.67

FMR Inc 2.61

Redmile Group, LLC 2.44

Fidelity Select Biotechnology 2.42

Alyeska Investment Group, L.P. 2.16

MPM Oncology Impact Management LP 2.10

Nantahala Capital Management, LLC 2.06

Franklin Resources Inc 2.05

iShares Russell 2000 ETF 1.86

Adage Capital Partners Gp LLC 1.80

Monashee Investment Management LLC 1.73

Point72 Asset Management, L.P. 1.71

Geode Capital Management, LLC 1.65

State Street Corp 1.40

Franklin Biotechnology Discv A(acc)USD 1.32

Franklin Biotechnology Discovery A 0.96

Fidelity Small Cap Index 0.74

iShares Russell 2000 Value ETF 0.64

Vanguard Institutional Extnd Mkt Idx Tr 0.64

International Biotechnology Ord 0.63

iShares Biotechnology ETF 0.57

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

Nuveen Equity Index R6 0.40

Vanguard Russell 2000 ETF 0.36

Fidelity Extended Market Index 0.31

SSgA Russell Small Cap Completeness Idx 0.29

Dimensional US Small Cap ETF 0.28

DFA US Small Cap I 0.27

State St Russell Sm Cap® Indx SL Cl I 0.24

iShares Micro-Cap ETF 0.20

Schwab Small Cap Index 0.19

SOLID BIOSCIENCES INC Market Status

Strong Buy: 7

Buy: 5

Hold: 0

Sell: 0

Strong Sell: 0

SOLID BIOSCIENCES INC Fundamentals

Market Cap 601.08 M

PB Ratio 2.7579

PE Ratio 0.0

Enterprise Value 386.87 M

Total Assets 188.66 M

Volume 1580379

SOLID BIOSCIENCES INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:8094000 8.1M, FY21:13620000 13.6M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:8094000 8.1M, FY21:13620000 13.6M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-90830000 -90.8M, FY22:-65510000 -65.5M, FY21:-72124000 -72.1M, FY20:-90118000 -90.1M, FY19:-115643000 -115.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-376000 -0.4M, Q2/2025:-386000 -0.4M, Q1/2025:-407000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-1235000 -1.2M

Quarterly Net worth Q3/2025:-45776000 -45.8M, Q2/2025:-39480000 -39.5M, Q1/2025:-39282000 -39.3M, Q3/2024:-32725000 -32.7M, Q2/2024:-25072000 -25.1M

About SOLID BIOSCIENCES INC & investment objective

Company Information Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Organisation Biotechnology

Employees 100

Industry Biotechnology

CEO Mr. Ilan Ganot

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow